Get the Stockscreener App
2.08
0.95%
-0.02
Sab Biotherapeutics Inc stock is traded at $2.08, with a volume of 18,994.
It is down -0.95% in the last 24 hours and down -8.17% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
18,994
Relative Volume:
0.01
Market Cap:
$21.66M
Revenue:
-
Net Income/Loss:
$-45.57M
P/E Ratio:
-0.3302
EPS:
-6.3
Net Cash Flow:
$-38.56M
1W Performance:
-5.22%
1M Performance:
-8.17%
6M Performance:
+23.08%
1Y Performance:
-28.28%
1-Day Range:
$2.03
$2.1192
1-Week Range:
$2.03
$2.29
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.08 | 19.51M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Stock (SABS) Latest News
What machine learning models say about SAB Biotherapeutics Inc.Index Update & Fast Entry High Yield Stock Tips - Newser
Technical analysis overview for SAB Biotherapeutics Inc. Equity Warrant stockWeekly Gains Report & Free Community Consensus Stock Picks - Newser
Will SAB Biotherapeutics Inc. Equity Warrant continue its uptrend2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Using Ichimoku Cloud for SAB Biotherapeutics Inc. technicals2025 Sector Review & Real-Time Buy Signal Notifications - Newser
Combining price and volume data for SAB Biotherapeutics Inc.2025 Big Picture & High Conviction Buy Zone Picks - Newser
Published on: 2025-08-31 21:03:02 - Newser
What candlestick patterns are forming on SAB Biotherapeutics Inc.July 2025 Technicals & Accurate Intraday Trading Signals - Newser
Using fundamentals and technicals on SAB Biotherapeutics Inc.Quarterly Portfolio Review & Free High Return Stock Watch Alerts - Newser
Intraday pattern recognizer results for SAB Biotherapeutics Inc. Equity Warrant2025 Price Targets & Low Risk Entry Point Tips - Newser
SAB Biotherapeutics Inc. Equity Warrant stock trend forecastDip Buying & Safe Entry Zone Tips - Newser
Using data tools to time your SAB Biotherapeutics Inc. exit2025 Geopolitical Influence & Risk Controlled Daily Trade Plans - Newser
What to expect from SAB Biotherapeutics Inc. Equity Warrant in the next 30 daysJuly 2025 Chart Watch & Risk Adjusted Buy and Sell Alerts - Newser
News impact scoring models applied to SAB Biotherapeutics Inc.2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Published on: 2025-08-31 12:37:30 - Newser
Key resistance and support levels for SAB Biotherapeutics Inc.Earnings Risk Report & Fast Momentum Entry Tips - Newser
Real time breakdown of SAB Biotherapeutics Inc. stock performanceJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Chart based analysis of SAB Biotherapeutics Inc. Equity Warrant trendsTreasury Yields & Weekly Market Pulse Updates - Newser
Analyzing recovery setups for SAB Biotherapeutics Inc. Equity Warrant investorsWeekly Stock Recap & Verified Entry Point Signals - Newser
What MACD signals say about SAB Biotherapeutics Inc.Weekly Trend Recap & Verified Short-Term Trading Plans - Newser
Will SAB Biotherapeutics Inc. Equity Warrant rebound enough to break evenExit Point & Expert Approved Momentum Ideas - Newser
Key metrics from SAB Biotherapeutics Inc.’s quarterly dataWeekly Loss Report & Daily Chart Pattern Signal Reports - Newser
Statistical indicators supporting SAB Biotherapeutics Inc. Equity Warrant’s strengthPortfolio Gains Summary & Safe Capital Growth Trade Ideas - Newser
SAB Biotherapeutics Inc. stock momentum explainedJuly 2025 Rallies & Low Drawdown Momentum Ideas - Newser
Is it time to cut losses on SAB Biotherapeutics Inc.July 2025 Closing Moves & Community Verified Trade Signals - Newser
SAB Biotherapeutics Inc. Equity Warrant stock chart pattern explainedEarnings Overview Report & Weekly Breakout Watchlists - Newser
Ranking SAB Biotherapeutics Inc. among high performing stocks via toolsTrade Volume Summary & Stock Market Timing Techniques - Newser
Multi asset correlation models including SAB Biotherapeutics Inc.2025 Biggest Moves & Weekly Momentum Stock Picks - Newser
How moving averages guide SAB Biotherapeutics Inc. tradingTrend Reversal & Risk Adjusted Buy/Sell Alerts - Newser
Chart overlay techniques for tracking SAB Biotherapeutics Inc. Equity Warrant2025 Market Outlook & Community Verified Trade Alerts - Newser
Sector ETF performance correlation with SAB Biotherapeutics Inc. Equity WarrantQuarterly Profit Review & Community Consensus Trade Signals - Newser
Using economic indicators to assess SAB Biotherapeutics Inc. potential2025 Support & Resistance & Free Safe Capital Growth Stock Tips - Newser
How to integrate SAB Biotherapeutics Inc. Equity Warrant into portfolio analysis toolsJuly 2025 Breakouts & Verified Entry Point Signals - Newser
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):